When it comes to clinical weight loss treatments, GLP-1 treatments took the medical sector through the storm. What began as the use of outside the name by celebrities and influencers on social media to reduce weight has become a viral feeling as diabetes was launched of type 2 of the GLP-1 direction. Novo Nordisk A/S. NYSE: NVO Smaglutide was formulated specially designed for obesity when they released Wegovy in June 2021.
Elie Lily and Partners New York: Li The dual GLP-1/GIP rods for obesity, Zepbound, in December 2023. Zepbound is the most effective GLP-1 for weight loss.
Between Novo and Lilly, the GLP-1 industry has become a monopoly with a lower threat than complexes such as HIMS & Her Health Inc. NYSE: HIMS After removing the drug deficiency list.
However, there was a sensation about a new GLP treatment from Viking Therapics Inc. Nasdak: VKTX This threatens to disrupt GLP-1 SuPoly.
Why can the work of the VK2735 weight loss market will be disrupted
VK2735. It is a dual GLP-1 GIP receptor, similar to Tirzepatide. GLP -1 (Betty -like glucagon -1) and GIP (infectious pollysis polybridge) are intestinal hormones responsible for driving appetite, insulin enhancement and weight memory in the end.
VK2735 is developed as an injection and mouth treatment. To become “wonderful”, it must meet effectively (the loss of great body weight), endurance (lower side effects), and something unique, such as doses comfort (oral delivery and shot once a month). Semaglutide (Novo) and Tirzepatide (Lilly) are gold standards. Here are the results of the last weight loss of each drug:
- Wegovy (Novo Nordisk) had a average weight loss by 14.9 % in weekly injection 2.4 mg after 68 weeks during the study of the third stage of the first step.
- Zepbound (ELI Lilly) had a average weight loss by 20.9 % in the 15mg weekly injection after 72 weeks in his studies in the third stage.
- VK2735 (VIKING) was 14.7 % on weekly injection 15 mg in only 13 weeks in the study of the second stage.
The game changed for speed and doses
Viking Therapeutics today
97.67 dollars
231.52 % upHe buys
Based on 13 analyst classifications
| The current price | $ 29.46 |
|---|---|
| High expectations | 138.00 dollars |
| Average expectations | 97.67 dollars |
| Low expectations | $ 38.00 |
Vicing treatments Details stock expectations
Various weekly courses such as comparing apples with orange may appear with different experimental periods. Comparative it by time for weight loss results is a significant shift. Show VK2735 Loss at lightning speed at 13.1 % of the modified weight loss in the placebo in 13 weeks. Compare this to the Zepbound strike, which reaches 20.1 % of the modified weight loss in the placebo in 72 weeks, and takes only 68 weeks for only 12.4 % of weight loss. The modified weight loss rate in fake loss takes 14.7 % and puts 1.7 % weight loss to the group that takes an imaginary drug to provide a more complete image.
VK2735 is twice the weight as soon as the Zepbound and the fastest 5x of Wegovy. However, the game changed is half the age of 171 days, indicating that it may come out with an injection once a month compared to the weekly injection of the occupants. This does not appeal to patients who want to lose weight faster and less painful injections, but also for health insurance companies who may end up choosing shorter periods than excessive, depending on prices. This is what is so enthusiastic analysts that it exports a high goal at $ 138 and $ 97.67 from the price of a consensus analyst even before receiving the approval of the FDA. Viking will conduct injection experience in stage 3 in the second quarter of 2025.
Why are the GLP-1 treatments for the largest money maker of Pharma giants?
Analysts estimate that the GLP-1 drug market grows from 90 billion dollars to $ 150 billion by 2030. GLP-1 drugs in Novo Smaglutide as an active component, while Terzopatide. These GLP-1 treatments have grown to calculate the largest parts of revenue. In 2024, Novo Nordisk reported a total revenue of $ 40.66 billion, which was attributed to $ 20.88 billion to the GLP-1 drugs, which represents 51.4 % of total revenue. For Eli Lilly, a total of 2024 revenues reached $ 45.04 billion, GLP-1 drugs achieved $ 16.4 billion, which represented 37 % of total revenue.
Great collection in making: Signing a long -term CDMO deal
In long -term studies, Zepbound is still the pioneer, but over time, VK2735 may exceed a 20.1 % placebo loss in 72 weeks. VK2735 weight loss was 13.1 % in only 13 weeks; If he can reach 20 % of the imaginary weight loss in less than 72 weeks, which is approximately certainty as there was no 13 -week -old study plateau, Viking has a proud of her hands. Viking is also confident enough to sign a long -term deal with Cordenpharma, the Organization for the Development and Manufacturing of Contracts (CDMO), to develop VK2735 drug and oral medicine.
Before you think of Vikings treatments, you will want to hear it.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whose senior analysts are quietly whispered to their customers to buy now before wiping the broader market … Viking Therapeutics was not in the list.
While Viking Therapeutics currently has a purchase classification between analysts, senior exporters analysts believe that these five stocks buy better.
Show the five stocks here
Enter your e -mail address and we will send you a MARKETBEAT Manual for Investing in 5G, which shows the largest 5G shares.
